Literature DB >> 18040692

Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection.

Byung Moon Kim1, Min Jung Kim, Eun-Kyung Kim, Sung Il Park, Cheong Soo Park, Woong Youn Chung.   

Abstract

The purpose of this study was to retrospectively evaluate the efficacy of ultrasonography-guided percutaneous ethanol injection (PEI) for neck recurrence of papillary thyroid carcinoma (NR-PTC). Twenty-seven patients (19-80 years old; mean, 53.2) with 47 NR-PTCs were treated by PEI and were followed-up (14-38 months; mean, 28.2). Ethanol (99%) was repeatedly injected with adjusting needle position until the entire volume of NR-PTC was ablated. All patients received follow-up ultrasonography at 3-6-month intervals, and the percent volume decrease was measured. The NR-PTCs with decreased volume and no tumor vascularity on power-Doppler study were regarded as treatment-effective. The NR-PTCs with stable or enlarged volume or with tumor vascularity were considered as treatment-failed, in which case PEI was repeated. The number of sessions and the total volume of ethanol per NR-PTC, and the volume of ethanol per session per NR-PTC were evaluated. All NR-PTCs significantly decreased in volume (range, 30-100%; mean, 93.6%). The mean number of sessions, the total volume of ethanol per NR-PTC, and the mean volume of ethanol per session per NR-PTC were 2.1 sessions (range 1-6), 2.4 ml (range 0.3-10.1), and 1.1 ml/session (range 0.3-3.0), respectively. PEI appears to be an alternative option for controlling NR-PTCs in the selected patients who are poor surgical candidates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040692     DOI: 10.1007/s00330-007-0809-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

1.  Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.

Authors:  Ian D Hay; William M McConahey; John R Goellner
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

2.  Percutaneous ethanol injection of large autonomous hyperfunctioning thyroid nodules.

Authors:  L Tarantino; A Giorgio; N Mariniello; G de Stefano; A Perrotta; V Aloisio; S Tamasi; M C Forestieri; F Esposito; F Esposito; L Finizia; A Voza
Journal:  Radiology       Date:  2000-01       Impact factor: 11.105

3.  Sonographically guided ethanol sclerotherapy for benign thyroid cysts: results in 22 patients.

Authors:  Y S Cho; H K Lee; I M Ahn; S M Lim; D H Kim; C G Choi; D C Suh
Journal:  AJR Am J Roentgenol       Date:  2000-01       Impact factor: 3.959

4.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

5.  Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis.

Authors:  N F Esnaola; S B Cantor; S I Sherman; J E Lee; D B Evans
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

6.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

7.  Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma.

Authors:  B D Lewis; I D Hay; J W Charboneau; B McIver; C C Reading; J R Goellner
Journal:  AJR Am J Roentgenol       Date:  2002-03       Impact factor: 3.959

8.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

9.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965

  10 in total
  10 in total

1.  Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.

Authors:  Sae Rom Chung; Jung Hwan Baek; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2019-02-25       Impact factor: 5.315

2.  Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer.

Authors:  Soo Young Kim; Seok-Mo Kim; Hojin Chang; Bup-Woo Kim; Chi Young Lim; Yong Sang Lee; Hang-Seok Chang; Cheong Soo Park
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-29       Impact factor: 2.503

3.  Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes.

Authors:  Guia Vannucchi; Danila Covelli; Michela Perrino; Simone De Leo; Laura Fugazzola
Journal:  Endocrine       Date:  2014-03-08       Impact factor: 3.633

4.  Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk.

Authors:  Enrico Papini; Rinaldo Guglielmi; Hossein Gharib; Gharib Hosseim; Irene Misischi; Filomena Graziano; Marco Chianelli; Anna Crescenzi; Antonio Bianchini; Dario Valle; Giancarlo Bizzarri
Journal:  Thyroid       Date:  2011-05-19       Impact factor: 6.568

Review 5.  Image-guided percutaneous ablation therapies for local recurrences of thyroid tumors.

Authors:  C M Pacella; E Papini
Journal:  J Endocrinol Invest       Date:  2013-01       Impact factor: 4.256

6.  Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer.

Authors:  Hyun Kyung Lim; Jung Hwan Baek; Jeong Hyun Lee; Won Bae Kim; Tae Yong Kim; Young Kee Shong; Suck Joon Hong
Journal:  Eur Radiol       Date:  2014-09-09       Impact factor: 5.315

Review 7.  Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.

Authors:  Loredana Lorusso; Letizia Pieruzzi; Agnese Biagini; Elena Sabini; Laura Valerio; Carlotta Giani; Paolo Passannanti; Benedetta Pontillo-Contillo; Valentina Battaglia; Salvatore Mazzeo; Eleonora Molinaro; Rossella Elisei
Journal:  Onco Targets Ther       Date:  2016-10-20       Impact factor: 4.147

8.  Single-Fiber Laser Ablation in Treating Selected Metastatic Lymph Nodes of Papillary Thyroid Carcinoma and Benign Cold Thyroid Nodules-Preliminary Results.

Authors:  YuQing Guo; ZhiXian Li; SiDa Wang; XianShan Liao; Chen Li
Journal:  Lasers Surg Med       Date:  2019-09-05       Impact factor: 4.025

Review 9.  Ethanol Ablation of the Thyroid Nodules: 2018 Consensus Statement by the Korean Society of Thyroid Radiology.

Authors:  Soo Yeon Hahn; Jung Hee Shin; Dong Gyu Na; Eun Joo Ha; Hye Shin Ahn; Hyun Kyung Lim; Jeong Hyun Lee; Jeong Seon Park; Ji Hoon Kim; Jin Yong Sung; Joon Hyung Lee; Jung Hwan Baek; Jung Hyun Yoon; Jung Suk Sim; Kwang Hwi Lee; Seon Mi Baek; So Lyung Jung; Yeo Koon Kim; Yoon Jung Choi
Journal:  Korean J Radiol       Date:  2019-04       Impact factor: 3.500

10.  Long-Term Efficacy of Ethanol Ablation as Treatment of Metastatic Lymph Nodes From Papillary Thyroid Carcinoma.

Authors:  Pål Stefan Frich; Eva Sigstad; Audun Elnæs Berstad; Kristin Holgersen Fagerlid; Trond Harder Paulsen; Trine Bjøro; Liv Ingrid Flinder
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.